One of the most prominent tobacco companies in the industry, British American Tobacco, has recently ventured into a plant-based biotechnology company.
The biotechnology company, called KBio Holdings Limited (KBio) and launched in the United Kingdom, aims to accelerate the research development and production of novel treatments.
Dr. Patrick Doyle, the executive officer of KBio, expressed excitement over this new development. He was thankful for the opportunity to make significant accomplishments by BAT and KBP working together.
In the same way, Dr. David O’Reilly, director of scientific research, said that the establishment of KBio is a vital step in the company’s efforts to shift into alternative combustible cigarette products.
Currently, KBio’s technology has proved its potential to manufacture high-purity new antibodies and vaccine candidates in a fraction of the time and expense of current methods.
According to O’Reilly, science and innovation are fundamental concepts in the company and contribute to the delivery of their purpose – building a better tomorrow. He also stated that the company recognizes the potential of its new plant-based technology.
That’s why they have established KBio to ensure they can maximize that potential and that they’re excited to see what the future holds for them and the company.